Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion type Assertion NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_head.
- NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_provenance.
- NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion evidence source_evidence_literature NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_provenance.
- NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion SIO_000772 20080466 NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_provenance.
- NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion wasDerivedFrom befree-20140225 NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_provenance.
- NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion wasGeneratedBy ECO_0000203 NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_provenance.